Literature DB >> 33723614

Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?

David Pesqué1, Blanca Sanchez-Gonzalez, Fernando Gallardo, Sonia Segura, Ramon M Pujol.   

Abstract

Entities:  

Keywords:  PI3K inhibitor; paradoxical reaction; psoriasis

Mesh：

Year:  2021        PMID： 33723614      PMCID： PMC9366692          DOI： 10.2340/00015555-3783

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  9 in total

Review 1.  Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer.

Authors:  Marcus D Goncalves; Benjamin D Hopkins; Lewis C Cantley
Journal:  N Engl J Med       Date:  2018-11-22       Impact factor: 91.245

Review 2.  PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.

Authors:  I Brian Greenwell; Andrew Ip; Jonathon B Cohen
Journal:  Oncology (Williston Park)       Date:  2017-11-15       Impact factor: 2.990

Review 3.  Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?

Authors:  Tian Huang; Xiran Lin; Xianmin Meng; Mao Lin
Journal:  Acta Derm Venereol       Date:  2014-07       Impact factor: 4.437

4.  Pharmacological inhibition of PI3K class III enhances the production of pro- and anti-inflammatory cytokines in dendritic cells stimulated by TLR agonists.

Authors:  Álvaro Pittini; Cecilia Casaravilla; Judith E Allen; Álvaro Díaz
Journal:  Int Immunopharmacol       Date:  2016-05-08       Impact factor: 4.932

5.  First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.

Authors:  Eric Helmer; Mark Watling; Emma Jones; Dominique Tytgat; Mark Jones; Rodger Allen; Andrew Payne; Annelize Koch; Eugene Healy
Journal:  Eur J Clin Pharmacol       Date:  2017-02-04       Impact factor: 2.953

Review 6.  Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon.

Authors:  Alessio Mylonas; Curdin Conrad
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561

7.  Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.

Authors:  Joo Hyun Kim; Won Seog Kim; Chaehwa Park
Journal:  BMC Cancer       Date:  2019-10-10       Impact factor: 4.430

8.  Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.

Authors:  Salma Machan; Carlos Plaza; Yosmar Pérez-González; Maria Rodriguez-Pinilla; Luis Requena; Raul Cordoba
Journal:  J Med Case Rep       Date:  2020-02-24
  9 in total
  1 in total

1.  Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review.

Authors:  Duy C Tran; Maria Karim; Kristen Lo Sicco; Nooshin Brinster; Emily C Milam; Ian W Tattersall
Journal:  JAAD Case Rep       Date:  2022-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.